Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study
At our VA hospital, in general, it is the policy of our GI lab to not stop our patients anti-platelet therapy whenever they see us for a routine colonoscopy. We do this because we believe the risk of stopping these sort of medications outweigh the risks of a complication from a colonoscopy.
Therefore, we are enrolling patients who are either on clopidogrel or prasugrel or not on any anti-platelet/anti-coagulant therapy that come to our GI lab routine colonoscopies. We perform the procedure just like we normally would and then follow-up with the patient 7 and 30 days after their procedure.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Study Start Date:||December 2009|
|Primary Completion Date:||March 2012 (Final data collection date for primary outcome measure)|
Patients who are not on any anti-platelet/anti-coagulant therapy and present to our lab for a elective colonoscopy.
Patients on Clopidogrel or prasugrel when they present for an elective colonoscopy.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01647568
|United States, Texas|
|Dallas VA Medical Center|
|Dallas, Texas, United States, 75216|